Why this £40m bet on an emerging cancer treatment may be perfectly...
Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million, as appetite for early-stage cancer therapies reaches new highs When Johnson and Johnson paid $3.05 …